Contemporary Management Of Stage T1 Transitional Cell Carcinoma Of The Bladder

Abstract

High grade stage T1 transitional cell carcinoma is a highly malignant tumor. Complete resection followed by immediate mitomycin C instillation and 6 weekly BCG instillations results in an acceptably low recurrence and progression rate. Rigorous long-term surveillance and continuous reconsideration of radical cystectomy in concordance with the evolution of the disease are essential.

Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors

“…Currently, radiation and chemotherapy are two major cancer treatments of bladder tumour (Kaufman et al, 2009). Nevertheless, it is a problem that the recurrence is still high (Soloway et al, 2002). Of newly diagnosed bladder cancer cases, although almost a quarter will present with non-muscle-invasive diseases and are not death threatening, however more than half of the patients will show the recurrences and most of those will be withi n five years (Sylvester et al, 2002).…”

Staging and reporting of urothelial carcinoma of the urinary bladder

“…16,[23][24][25]27,30 This is probably due to intrinsic difficulty in assessing the presence and extent of invasion. An accurate, easy-to-use, reproducible substaging system is needed to stratify pT1 patients into prognostically distinct groups.…”

Genetic alterations in urothelial bladder carcinoma

“…Patients with pTa tumors frequently undergo transurethral bladder resection and receive intravesical therapy (bacillus Calmette-Guerin and mitomycin), and patients with pT2 tumors undergo cystectomy with or without preoperative and/or postoperative chemotherapy. 2,3 Conversely, pT1 tumors still constitute the major problem that faces both urologists and oncologists, because pT1 tumors may be treated as either pTa tumors or pT2 tumors. 4,5 To provide the best care for patients with UC, new prognostic and predictive markers are needed.…”